Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Ensysce Biosciences, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +3 vs. Q4 2021
- Shares held
- 5.47M
- +2.09M (+61.8%) vs. Q4 2021
- Total value
- $6.23M
- −$9.64M (−60.8%) vs. Q4 2021
- New holders
- 7
- 4 more added
- Sold out
- 4
- 5 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $810.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HG Vora Capital Management, LLC | 2,462,500 | $2.81M | 0.08% | 00.0% | Unchanged |
| Anson Funds Management LP | 1,875,367 | $2.14M | 0.29% | +1,875,367 | New |
| Renaissance Technologies LLC | 287,661 | $328.0K | 0.00% | +287,661 | New |
| BlackRock Inc. | 234,240 | $267.0K | 0.00% | +233,679+41,654.0% | Added |
| Stifel Financial Corp | 216,642 | $247.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 122,353 | $140.0K | 0.00% | −178,946−59.4% | Reduced |
| Geode Capital Management, LLC | 110,246 | $125.0K | 0.00% | +9,325+9.2% | Added |
| Powell Investment Advisors, LLC | 50,000 | $57.0K | 0.03% | +50,000 | New |
| State Street Corp | 35,551 | $41.0K | 0.00% | +651+1.9% | Added |
| Virtu Financial LLC | 24,630 | $28.0K | 0.00% | +24,630 | New |
| Evergreen Capital Management LLC | 11,534 | $13.0K | 0.00% | −2,494−17.8% | Reduced |
| Cresset Asset Management, LLC | 11,223 | $13.0K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 10,226 | $12.0K | 0.00% | −22,227−68.5% | Reduced |
| UBS Group AG | 7,974 | $9.00K | 0.00% | −1,887−19.1% | Reduced |
| Wolverine Asset Management LLC | 4,987 | $5.00K | 0.00% | +1,527+44.1% | Added |
| FinTrust Capital Advisors, LLC | 350 | $0 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 270 | $0 | 0.00% | −39−12.6% | Reduced |
| Wells Fargo & Company | 64 | $0 | 0.00% | 00.0% | Unchanged |
| Covington Capital Management | 100 | $0 | 0.00% | +100 | New |
| Cutler Group LP | 100 | $0 | 0.00% | +100 | New |
| FNY Investment Advisers, LLC | 20 | $0 | 0.00% | +20 | New |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −170,648−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −16,733−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1,314−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −91−100.0% | Sold out |